Neuralstem (CUR) was Initiated by ROTH Capital to “Buy” and the brokerage firm has set the Price Target at $1.20. ROTH Capital advised their investors in a research report released on Aug 29, 2016.
Neuralstem closed down -0.0029 points or -1.05% at $0.274 with 2,86,086 shares getting traded on Tuesday. Post opening the session at $0.28, the shares hit an intraday low of $0.265 and an intraday high of $0.2898 and the price fluctuated in this range throughout the day.Shares ended Tuesday session in Red.
In a different news, on Nov 16, 2015, Karl Johe (Chief Scientific Officer) sold 25,000 shares at $1.09 per share price.
Neuralstem Inc. (Neuralstem) is engaged in development and commercialization of regenerative medicine treatments based on its human neuronal stem cells and its small molecule compounds. Neuralstem’s technology enables the isolation and expansion of human neural stem cells from all areas of the developing human brain and spinal cord thus enabling the generation of physiologically relevant human neurons of all types. It has developed and patented a series of small molecule compounds. The Company is developing products using technology including Cell Therapy and Small Molecule Pharmaceutical Compounds. The Company has a wholly owned subsidiary Suzhou Sun-Now Biopharmaceutical Co. Ltd. in China. Its clinical programs include the NSI-566 and NSI-189.